This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)

This study has been completed.
Information provided by (Responsible Party):
Mesoblast, Ltd. ( Mesoblast International Sàrl ) Identifier:
First received: April 7, 2009
Last updated: August 29, 2017
Last verified: August 2017
The objective of the present study is to establish the safety and efficacy of Prochymal® following first acute myocardial infarction.

Condition Intervention Phase
Myocardial Infarction Drug: Prochymal® Drug: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II, Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of PROCHYMAL® (Ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction

Resource links provided by NLM:

Further study details as provided by Mesoblast, Ltd. ( Mesoblast International Sàrl ):

Primary Outcome Measures:
  • Left ventricular end systolic volume [ Time Frame: 3 months ]

Secondary Outcome Measures:
  • Left ventricular end systolic volume [ Time Frame: 6 months ]
  • Infarct size [ Time Frame: 3 and 6 months ]
  • Left ventricular ejection fraction [ Time Frame: 3 and 6 months ]
  • Left ventricular end diastolic volume [ Time Frame: 3 and 6 months ]
  • Incidence of ventricular arrhythmias [ Time Frame: 3 and 6 months ]
  • Cardiovascular disease-specific quality of life (DASI) assessment [ Time Frame: 6, 12, and 24 months ]
  • NYHA congestive heart failure classification status [ Time Frame: 6, 12, 24, and 60 months ]
  • Maximal symptom-limited exercise test (treadmill) [ Time Frame: 6 and 12 months ]
  • MACE endpoints [ Time Frame: 6, 12, 24, and 60 months ]
  • Survival Status [ Time Frame: 60 months ]
  • Adverse Event [ Time Frame: 3,6,12,24,60 months ]

Enrollment: 220
Study Start Date: March 2009
Study Completion Date: August 2016
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Prochymal®
200M Mesenchymal Stem Cell (MSC) administered via IV infusion
Drug: Prochymal®
Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells
Placebo Comparator: Placebo
Placebo via IV infusion
Drug: Placebo
Intravenous infusion of excipients of Prochymal®

Detailed Description:
The standard of care treatment for acute myocardial infarction (AMI) usually includes immediate perfusion, optimal pain relief, oxygen, aspirin or other anti-coagulants, Beta-Blockers, nitrates and Ace-inhibitors. However, because salvaging the viable myocardium is dependent on early reperfusion, only a minority of patients will reach the hospital within the time-window for myocardial rescue. Thus, even if the patient manages their tobacco use, hypertension, lipid levels, diabetes, weight and exercise, many patients will go on to develop Congestive Heart Failure (CHF). Though the medical management for CHF may improve symptoms and slow disease progression, such treatment cannot restore a functioning myocardium. A therapy that could improve the myocardial remodeling process and reduce the incidence or severity of CHF following acute MI would provide a significant benefit. The characteristics and biologic activity of Prochymal®, along with a good safety profile in human trials to date, suggest that Prochymal® may be a good candidate for addressing this unmet medical need.

Ages Eligible for Study:   21 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Male or female between 21 and 85 years old, inclusive
  • First heart attack within 7 days prior to randomization and drug infusion
  • Baseline LVEF 20-45%
  • Hemodynamically stable within 24 hours prior to randomization
  • Adequate pulmonary function

Exclusion Criteria:

  • Previous medical history of heart attack, heart failure, significant valvular heart disease, aortic dissection
  • Pacemaker or other device
  • Pregnant, breast-feeding, or intends to become pregnant during the study
  • Allergy to cow or pig derived products
  • Evidence of active malignancy or prior history of active malignancy
  • Major surgical procedure or major trauma within the past 14 days
  • Autoimmune disease (e.g., Lupus, Multiple Sclerosis)
  • Any medical condition, which in the opinion of the Investigator, renders participation unsuitable
  • Undergone pharmacologic cardioversion or external defibrillation within 24 hours of randomization.
  • Experienced cardiac arrest more than 36 hours after presentation to site or within 24 hours of randomization.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00877903

  Show 33 Study Locations
Sponsors and Collaborators
Mesoblast International Sàrl
Study Director: Donna Skerrett, MD Mesoblast, Inc.
  More Information

Responsible Party: Mesoblast International Sàrl Identifier: NCT00877903     History of Changes
Other Study ID Numbers: 403
Study First Received: April 7, 2009
Last Updated: August 29, 2017

Keywords provided by Mesoblast, Ltd. ( Mesoblast International Sàrl ):
Acute myocardial infarction
Myocardial infarction
Heart attack
Mesenchymal stem cells
Adult human stem cells

Additional relevant MeSH terms:
Myocardial Infarction
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases processed this record on September 21, 2017